Consensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease (Q30245434)

12 June 2017

1 reference

title

Consensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease (English)

1 reference

12 June 2017

11

0 references

Alessandro Mugelli

9

0 references

author name string

Maria Serenella Pignotti

1

1 reference

12 June 2017

Maria Carmela Leo

2

1 reference

12 June 2017

Alessandra Pugi

3

1 reference

12 June 2017

Salvatore De Masi

4

1 reference

12 June 2017

Klaus Peter Biermann

5

1 reference

12 June 2017

Luisa Galli

6

1 reference

12 June 2017

Giovanni Vitali Rosati

7

1 reference

12 June 2017

Giuseppe Buonocore

8

1 reference

12 June 2017

Carlo Dani

10

1 reference

12 June 2017

Francesca Bellini

12

1 reference

12 June 2017

Giampaolo Donzelli

13

1 reference

12 June 2017

Palivizumab Consensus Group

14

1 reference

12 June 2017

publication date

12 September 2016

1 reference

12 June 2017

published in

Pediatric Pulmonology

1 reference

12 June 2017

volume

51

1 reference

12 June 2017

issue

10

1 reference

12 June 2017

page(s)

1088-1096

1 reference

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

12 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Where are we with RSV prophylaxis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Palivizumab prophylaxis: does it have any influence on the growth and development of the infants?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Respiratory syncytial virus and recurrent wheeze in healthy preterm infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Randomized, Double-Blind Study of the Pharmacokinetics and Safety of Palivizumab Liquid Formulation Compared with Lyophilized Formulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Lower respiratory tract illness and RSV prophylaxis in very premature infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

CARESS: the Canadian registry of palivizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Palivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001: Results from the palivizumab outcomes registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Risk factors for bronchiolitis hospitalization during the first year of life in a multicenter Italian birth cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

The burden of respiratory syncytial virus infection in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Outcomes of palivizumab prophylaxis for respiratory syncytial virus infection in preterm children with bronchopulmonary dysplasia at a single hospital in Korea from 2005 to 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Safety of palivizumab in preterm infants 29 to 32 weeks' gestational age without chronic lung disease to prevent serious respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Cost-effectiveness of palivizumab in New Zealand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Randomized, Double-Blind Study of the Safety of the Liquid Versus Lyophilized Formulation of Palivizumab in Premature Infants and Children with Chronic Lung Disease of Prematurity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Evaluating national guidelines for the prophylactic treatment of respiratory syncytial virus in children with congenital heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Respiratory syncytial virus immunoprophylaxis in high-risk infants with heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Hospitalization for respiratory syncytial virus illness in Down syndrome following prophylaxis with palivizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Does prophylaxis with palivizumab reduce hospitalisation rates for respiratory-syncytial-virus-related infection in cystic fibrosis children less than 2 years of age?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Is palivizumab effective as a prophylaxis of respiratory syncytial virus infections in cystic fibrosis patients? A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Use of Palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

Bronchopulmonary dysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.23561

21 January 2018

Identifiers

DOI

10.1002/PPUL.23561

1 reference

12 June 2017

1 reference